Study summary · research use only
[Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this mouse study, female transgenic FVB mice carrying the mammary erbB-2/neu oncogene received subcutaneous injections of saline (control), the peptide Vilon (Lys-Glu), or Epitalon (Ala-Glu-Asp-Glu) for 5 days each month starting at age 2 months. Tumor characteristics did not differ between groups until 9 months of age. Afterward, the Epitalon group showed fewer tumors: one tumor per animal occurred in 7% of controls, 4% of the Vilon group, and 16% of the Epitalon group, while two or more tumors occurred in 75%, 95%, and 56% respectively. Maximum tumor diameter in the Epitalon group was 33% smaller than controls, and lung metastasis incidence was 2.6 times higher in the Vilon group than the Epitalon group. The authors reported reduced mammary carcinogenesis with Epitalon in this model.
Abstract
Female transgenic FVB mice transfected with the mammary erbB-2/neu oncogene were injected 0.1 ml 0.9% solution of sodium chloride (control), 1 meg Vilon peptide (Lys-Glu) or Epitalon peptide (Ala-Glu-Asp-Glu), s.c., 5 days in succession once a month, beginning from the age of 2 months. The characteristics of mammary tumor induction in the control and experimental groups did not differ until the age of 9 months. Later on, Epitalon-treated mice revealed distinct inhibition of carcinogenesis. One tumor per animal was detected in 7% (control), 4% (Vilon) and 16% (Epitalon) (p < 0.05). Two or more tumors per animal were in 75%, 95% and 56%, respectively (p < 0.05). Largest diameter of mammary adenocarcinoma in the Epitalon group was smaller than in controls by 33% (p < 0.05). Although the number of mice with metastases to the lung in all three groups was practically identical, their incidence in the Vilon group was 2.6 times higher than in Epitalon-treated animals (p < 0.05). Largest diameter of metastasis in the Epitalon group was the smallest, too. Our data point to inhibition of mammary carcinogenesis by Epitalon in transgenic erbB-2/neu mice.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.